Whitehawk Therapeutics, Inc. - Common Stock (WHWK)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — May 17, 2026Investment Snapshot
- Trading 10% below Graham Number — thin margin of safety
- Piotroski F-Score 2/9 — signs of financial weakness
- Loss-making — negative ROE of -16.8%
- Revenue declining 73% annually
Whitehawk Therapeutics, Inc. - Common Stock (WHWK) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $232 million . Key value metrics: P/E ratio 13.1, P/B ratio 2.00, Piotroski F-Score 2 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Whitehawk Therapeutics, Inc. - Common Stock — Fundamental Analysis Summary
Whitehawk Therapeutics, Inc. - Common Stock (WHWK) is trading 10% below its Graham Number of $5.20, offering a thin margin of safety. The stock carries a reasonable trailing P/E ratio of 13.1x.
On financial health, WHWK shows a weak Piotroski F-Score of 2/9, a signal of deteriorating financial health, and negative return on equity of -16.8% (sector average: -20.6%), and minimal leverage with a debt-to-equity ratio of 0.06.
StockPik's composite Value Score for WHWK is 42/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
WHWK reports a high gross margin of 89.4% (sector average: 40.1%) and a negative operating margin of -1,582.0%.
WHWK shows revenue declining at 73% year-over-year, with earnings growing at 68%.